Search

Your search keyword '"van Erpecum, Karel J."' showing total 680 results
Start Over Author "van Erpecum, Karel J."
680 results on '"van Erpecum, Karel J."'

5. Addition of PEG‐interferon to long‐term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg‐negative chronic hepatitis B

Author

Farag, Mina S., primary, van Campenhout, Margo J. H., additional, Sonneveld, M. J., additional, Fung, Scott, additional, van Erpecum, Karel J., additional, Wong, David K., additional, Verhey, Elke, additional, de Man, Robert, additional, De Knegt, Robert J., additional, Brouwer, Johannes T., additional, Baak, Hubertus C., additional, Feld, Jordan J., additional, Liem, Kin Seng, additional, Boonstra, André, additional, Hansen, Bettina E., additional, and Janssen, Harry L. A., additional

Published
2024
Full Text
View/download PDF

8. Increased Mortality Among Patients With vs Without Cirrhosis and Autoimmune Hepatitis

Author

Schreuder, T.C.M.A., van der Wouden, E.J., van Meyel, J.J.M., Baak, L.C., Stadhouders, P.H.G.M., Klemt-Kropp, M., Verhagen, M.A.M.T., Bhalla, A., Kuijvenhoven, J.Ph., van den Brand, Floris F., van der Veen, Koen S., de Boer, Ynto S., van Gerven, Nicole M., Lissenberg-Witte, Birgit I., Beuers, Ulrich, van Erpecum, Karel J., van Buuren, Henk R., den Ouden, Jannie W., Brouwer, Johannus T., Vrolijk, Jan M., Verdonk, Robert C., van Hoek, Bart, Koek, Ger H., Drenth, Joost P.H., Guichelaar, Marleen M.J., Mulder, Chris J.J., Bloemena, Elisabeth, van Nieuwkerk, Carin M.J., and Bouma, Gerd

Published
2019
Full Text
View/download PDF

9. Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease.

Author

Nijmeijer, Rian M, Gadaleta, Raffaella M, van Mil, Saskia WC, van Bodegraven, Adriaan A, Crusius, J Bart A, Dijkstra, Gerard, Hommes, Daan W, de Jong, Dirk J, Stokkers, Pieter CF, Verspaget, Hein W, Weersma, Rinse K, van der Woude, C Janneke, Stapelbroek, Janneke M, Schipper, Marguerite EI, Wijmenga, Cisca, van Erpecum, Karel J, Oldenburg, Bas, and Dutch Initiative on Crohn, Colitis (ICC)

Subjects
Dutch Initiative on Crohn, Colitis, Colon, Ileum, Humans, Colitis, Ulcerative, Inflammatory Bowel Diseases, Receptors, Cytoplasmic and Nuclear, RNA, Messenger, Case-Control Studies, Gene Expression, Polymorphism, Single Nucleotide, Female, Male, Genetic Variation, General Science & Technology
Abstract

BackgroundWe previously showed that activation of the bile salt nuclear receptor Farnesoid X Receptor (FXR) protects against intestinal inflammation in mice. Reciprocally, these inflammatory mediators may decrease FXR activation. We investigated whether FXR activation is repressed in the ileum and colon of inflammatory bowel disease (IBD) patients in remission. Additionally, we evaluated whether genetic variation in FXR is associated with IBD.MethodsmRNA expression of FXR and FXR target gene SHP was determined in ileal and colonic biopsies of patients with Crohn's colitis (n = 15) and ulcerative colitis (UC; n = 12), all in clinical remission, and healthy controls (n = 17). Seven common tagging SNPs and two functional SNPs in FXR were genotyped in 2355 Dutch IBD patients (1162 Crohn's disease (CD) and 1193 UC) and in 853 healthy controls.ResultsmRNA expression of SHP in the ileum is reduced in patients with Crohn's colitis but not in patients with UC compared to controls. mRNA expression of villus marker Villin was correlated with FXR and SHP in healthy controls, a correlation that was weaker in UC patients and absent in CD patients. None of the SNPs was associated with IBD, UC or CD, nor with clinical subgroups of CD.ConclusionsFXR activation in the ileum is decreased in patients with Crohn's colitis. This may be secondary to altered enterohepatic circulation of bile salts or transrepression by inflammatory signals but does not seem to be caused by the studied SNPs in FXR. Increasing FXR activity by synthetic FXR agonists may have benefit in CD patients.

Published
2011

13. Disease burden in primary sclerosing cholangitis in the Netherlands:A long-term follow-up study

Author

van Munster, Kim N., Mol, Bregje, Goet, Jorn C., van Munster, Sanne N., Weersma, Rinse K., de Vries, Annemarie C., van der Meer, Adriaan J., Inderson, Akin, Drenth, Joost P., van Erpecum, Karel J., Boonstra, Kirsten, Beuers, Ulrich, Dijkgraaf, Marcel G.W., Ponsioen, Cyriel Y., van Munster, Kim N., Mol, Bregje, Goet, Jorn C., van Munster, Sanne N., Weersma, Rinse K., de Vries, Annemarie C., van der Meer, Adriaan J., Inderson, Akin, Drenth, Joost P., van Erpecum, Karel J., Boonstra, Kirsten, Beuers, Ulrich, Dijkgraaf, Marcel G.W., and Ponsioen, Cyriel Y.

Abstract

Background & Aims: Primary sclerosing cholangitis (PSC) is a progressive, cholestatic liver disease which greatly impacts the lives of individuals. Burden of disease due to shortened life expectancy and impaired quality of life is ill-described. The aim of this study was to assess long-term disease burden in a large population-based registry with regard to survival, clinical course, quality adjusted life years (QALYs), medical consumption and work productivity loss. Methods: All PSC patients living in a geographically defined area covering ~50% of the Netherlands were included, together with patients from the three liver transplant centres. Survival was estimated by competing risk analysis. Proportional shortfall of QALYs during disease course was measured relative to a matched reference cohort using validated questionnaires. Work productivity loss and medical consumption were evaluated over time. Results: A total of 1208 patients were included with a median follow-up of 11.2 year. Median liver transplant-free survival was 21.0 years. Proportional shortfall of QALYs increased to 48% >25 years after diagnosis. Patients had on average 12.4 hospital contact days among which 3.17 admission days per year, annual medical costs were €12 169 and mean work productivity loss was 25%. Conclusions: Our data quantify for the first time disease burden in terms of QALYs lost, clinical events, medical consumption, costs as well as work productivity loss, and show that all these are substantial and increase over time.

Published
2023

14. Systematic review with meta-analysis: branched-chain amino acid supplementation in liver disease

Author

Afdeling Dietetiek, Cancer, Epi Kanker Team C, MS Hoofd-Hals Chirurgische Oncologie, VS-DIGD, MS MDL 1, Infection & Immunity, van Dijk, Anne M, Bruins Slot, Alexandra S, Portincasa, Piero, Siegerink, Sebastiaan N, Chargi, Najiba, Verstraete, Carina J R, Bruijne, Joep de, Vleggaar, Frank P, van Erpecum, Karel J, Afdeling Dietetiek, Cancer, Epi Kanker Team C, MS Hoofd-Hals Chirurgische Oncologie, VS-DIGD, MS MDL 1, Infection & Immunity, van Dijk, Anne M, Bruins Slot, Alexandra S, Portincasa, Piero, Siegerink, Sebastiaan N, Chargi, Najiba, Verstraete, Carina J R, Bruijne, Joep de, Vleggaar, Frank P, and van Erpecum, Karel J

Published
2023

15. Liver-related complications before and after successful treatment of chronic hepatitis C virus infection in people with inherited bleeding disorders

Author

Poli Van Creveldkliniek Medisch, MS MDL 1, Infection & Immunity, Cancer, Child Health, Circulatory Health, MS Interne Geneeskunde, Isfordink, Cas J., van Erpecum, Karel J., Fischer, Kathelijn, van der Valk, Paul R., van Vulpen, Lize F.D., Schutgens, Roger E.G., Arends, Joop E., Mauser-Bunschoten, Evelien P., Poli Van Creveldkliniek Medisch, MS MDL 1, Infection & Immunity, Cancer, Child Health, Circulatory Health, MS Interne Geneeskunde, Isfordink, Cas J., van Erpecum, Karel J., Fischer, Kathelijn, van der Valk, Paul R., van Vulpen, Lize F.D., Schutgens, Roger E.G., Arends, Joop E., and Mauser-Bunschoten, Evelien P.

Published
2023

17. Disease burden in primary sclerosing cholangitis in the Netherlands: A long-term follow-up study

Author

van Munster, Kim N., Mol, Bregje, Goet, Jorn C., van Munster, Sanne N., Weersma, Rinse K., de Vries, Annemarie C., van der Meer, Adriaan J., Inderson, Akin, Drenth, Joost P., van Erpecum, Karel J., Boonstra, Kirsten, Beuers, Ulrich, Dijkgraaf, Marcel G.W., Ponsioen, Cyriel Y., Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), and Gastroenterology & Hepatology

Subjects
disease burden, QALY, SDG 3 - Good Health and Well-being, PSC, work productivity loss, survival, medical costs
Abstract

Background & Aims: Primary sclerosing cholangitis (PSC) is a progressive, cholestatic liver disease which greatly impacts the lives of individuals. Burden of disease due to shortened life expectancy and impaired quality of life is ill-described. The aim of this study was to assess long-term disease burden in a large population-based registry with regard to survival, clinical course, quality adjusted life years (QALYs), medical consumption and work productivity loss. Methods: All PSC patients living in a geographically defined area covering ~50% of the Netherlands were included, together with patients from the three liver transplant centres. Survival was estimated by competing risk analysis. Proportional shortfall of QALYs during disease course was measured relative to a matched reference cohort using validated questionnaires. Work productivity loss and medical consumption were evaluated over time. Results: A total of 1208 patients were included with a median follow-up of 11.2 year. Median liver transplant-free survival was 21.0 years. Proportional shortfall of QALYs increased to 48% >25 years after diagnosis. Patients had on average 12.4 hospital contact days among which 3.17 admission days per year, annual medical costs were €12 169 and mean work productivity loss was 25%. Conclusions: Our data quantify for the first time disease burden in terms of QALYs lost, clinical events, medical consumption, costs as well as work productivity loss, and show that all these are substantial and increase over time.

Published
2023

23. Health-related quality of life in patients with primary sclerosing cholangitis

Author

Mol, Bregje, van Munster, Kim N., Bogaards, Johannes A., Weersma, Rinse K., Inderson, Akin, de Groof, E. Joline, Rossen, Noortje G.M., Ponsioen, Willemijn, Turkenburg, Maud, van Erpecum, Karel J., Poen, Alexander C., Spanier, B. W.Marcel, Beuers, Ulrich H.W., Ponsioen, Cyriel Y., Epidemiology and Data Science, AII - Infectious diseases, APH - Methodology, Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), Gastroenterology and Hepatology, Graduate School, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Surgery, Tytgat Institute for Liver and Intestinal Research, CCA - Cancer Treatment and Quality of Life, and CCA - Cancer biology and immunology

Subjects
health-related quality of life, Hepatology, inflammatory bowel disease, post-transplant, primary sclerosing cholangitis, population-based cohort, repeated measurements
Abstract

Background & Aims: Data regarding health-related quality of life (HRQoL) in primary sclerosing cholangitis (PSC) are sparse and have only been studied cross-sectionally in a disease which runs a fluctuating and unpredictable course. We aim to describe HRQoL longitudinally by using repeated measurements in a population-based cohort. Methods: Every 3 months from May 2017 up to August 2020, patients received digital questionnaires at home. These included the EQ-5D, 5-D Itch, patient-based SCCAI and patient-based HBI. The SF-36, measuring HRQoL over eight dimensions as well as a physical component summary (PCS) and mental component summary (MCS) score, was sent annually. Data were compared with Dutch reference data and a matched IBD disease control from the population-based POBASIC cohort. Mixed-effects modelling was performed to identify factors associated with HRQoL. Results: Three hundred twenty-eight patients completed 2576 questionnaires. A significant reduction of small clinical relevance in several mean HRQoL scores was found compared with the Dutch reference population: 46.4 versus 48.0, p =.018 for PCS and 47.5 versus 50.5, p =.004 for MCS scores. HRQoL outcomes were significantly negatively associated with coexisting active IBD (PCS −12.2, p

Published
2023

26. Health-related quality of life in patients with primary sclerosing cholangitis: a longitudinal population-based cohort study

Author

Mol, Bregje, van Munster, Kim, Bogaards, Johannes, Weersma, Rinse, Inderson, Akin, de Groof, Joline, Rossen, Noortje, Ponsioen, Willemijn, Turkenburg, Maud, van Erpecum, Karel J., Poen, Alexander, Spanier, B. W. Marcel, Beuers, Ulrich, Ponsioen, Cyriel, Gastroenterology and hepatology, AII - Infectious diseases, Amsterdam Gastroenterology Endocrinology Metabolism, Medical oncology, and APH - Methodology

Published
2022

27. Safety and Efficacy of166Ho Radioembolization in Hepatocellular Carcinoma: The HEPAR Primary Study

Author

Reinders, Margot T.M., primary, van Erpecum, Karel J., additional, Smits, Maarten L.J., additional, Braat, Arthur J.A.T., additional, Bruijne, Joep de, additional, Bruijnen, Rutger, additional, Sprengers, Dave, additional, Man, Robert A. de, additional, Vegt, Erik, additional, IJzermans, Jan N.M., additional, Moelker, Adriaan, additional, and Lam, Marnix G.E.H., additional

Published
2022
Full Text
View/download PDF

28. Real-life data on the impact of successful downstaging in patients with hepatocellular carcinoma:A Dutch Multicenter Study

Author

Broekhoven, Annelotte G.C., Fiocco, Marta, Sprengers, Dave, Takkenberg, R. Bart, van Meer, Suzanne, van Erpecum, Karel J., Ramsoekh, Dewkoemar, Verspaget, Hein W., Burgmans, Mark C., Osanto, Susanne, Baranski, Andrzej G., van Hoek, Bart, Coenraad, Minneke J., Broekhoven, Annelotte G.C., Fiocco, Marta, Sprengers, Dave, Takkenberg, R. Bart, van Meer, Suzanne, van Erpecum, Karel J., Ramsoekh, Dewkoemar, Verspaget, Hein W., Burgmans, Mark C., Osanto, Susanne, Baranski, Andrzej G., van Hoek, Bart, and Coenraad, Minneke J.

Abstract

Patients with Barcelona Clinic Liver Cancer intermediate stage hepatocellular carcinoma (HCC) theoretically are an excellent group to consider downstaging using locoregional therapy (LRT) since they do not have extrahepatic spread or vascular invasion. Once successful, this can change the treatment strategy from palliative to curative intention. Although downstaging therapy is suggested in guidelines, it is still not widely accepted. Moreover, studies on downstaging are mainly performed in high-incidence HCC countries. Therefore, our aim was to gain insight in therapeutic strategies in patients with intermediate stage HCC and their impact on intention-to-treat survival in a real-life setting in a low-incidence HCC country. We retrospectively analyzed data from the national Dutch HCC registry. From this database, consisting of 1409 patients with a diagnosis of HCC between 2005-2013 in 5 Dutch tertiary referral centers, we identified 165 patients with intermediate stage HCC. Out of these patients, 63 (38%) were not offered LRT, whereas 102 (62%) did receive LRT. Subsequently, 50 (49%) of the 102 patients who received LRT were successfully downstaged. Eleven patients (22% of successfully downstaged patients) eventually underwent liver transplantation. Cox regression analysis showed that a lower MELD score, an AFP value <100 ng/ml, successful downstaging and liver transplantation (all ≤p = 0.01) were positively associated to overall survival. In conclusion, our results demonstrate that LRT is not routinely offered to intermediate stage HCC patients in the Netherlands. Nevertheless, we showed that patients with intermediate stage HCC who are successfully downstaged have a survival benefit compared to those who were not.

Published
2022

29. Safety and Efficacy of 166Ho Radioembolization in Hepatocellular Carcinoma: The HEPAR Primary Study

Author

Cancer, Researchgr. Nucleaire Geneeskunde, MS MDL 1, Infection & Immunity, MS Radiologie, Other research (not in main researchprogram), Reinders, Margot T.M., van Erpecum, Karel J., Smits, Maarten L.J., Braat, Arthur J.A.T., Bruijne, Joep de, Bruijnen, Rutger, Sprengers, Dave, Man, Robert A.de, Vegt, Erik, IJzermans, Jan N.M., Moelker, Adriaan, Lam, Marnix G.E.H., Cancer, Researchgr. Nucleaire Geneeskunde, MS MDL 1, Infection & Immunity, MS Radiologie, Other research (not in main researchprogram), Reinders, Margot T.M., van Erpecum, Karel J., Smits, Maarten L.J., Braat, Arthur J.A.T., Bruijne, Joep de, Bruijnen, Rutger, Sprengers, Dave, Man, Robert A.de, Vegt, Erik, IJzermans, Jan N.M., Moelker, Adriaan, and Lam, Marnix G.E.H.

Published
2022

30. Nutritional status in patients with hepatocellular carcinoma: Potential relevance for clinical outcome

Author

Afdeling Dietetiek, MS Hoofd-Hals Chirurgische Oncologie, VS-DIGD, MS MDL 1, Cancer, Infection & Immunity, van Dijk, Anne M, Coppens, Bart J P, van Beers, Maartje A, Bruins Slot, Alexandra S, Verstraete, Carina J R, de Bruijne, Joep, Vleggaar, Frank P, van Erpecum, Karel J, Afdeling Dietetiek, MS Hoofd-Hals Chirurgische Oncologie, VS-DIGD, MS MDL 1, Cancer, Infection & Immunity, van Dijk, Anne M, Coppens, Bart J P, van Beers, Maartje A, Bruins Slot, Alexandra S, Verstraete, Carina J R, de Bruijne, Joep, Vleggaar, Frank P, and van Erpecum, Karel J

Published
2022

32. Non-alcoholic fatty liver disease: identical etiologic factors in patients with type 1 and type 2 diabetes

Author

Endocrinologie, Unit Opleiding Aios, MS MDL 1, Infection & Immunity, Cancer, MS Interne Geneeskunde, Circulatory Health, Unit Opleiding MDL, de Vries, Marieke, El-Morabit, Fatima, van Erpecum, Karel J., Westerink, Jan, Bac, Simon T., Kaasjager, H. A.H.(Karin), de Valk, Harold W., Endocrinologie, Unit Opleiding Aios, MS MDL 1, Infection & Immunity, Cancer, MS Interne Geneeskunde, Circulatory Health, Unit Opleiding MDL, de Vries, Marieke, El-Morabit, Fatima, van Erpecum, Karel J., Westerink, Jan, Bac, Simon T., Kaasjager, H. A.H.(Karin), and de Valk, Harold W.

Published
2022

35. Systematic review with meta‐analysis: Branched‐chain amino acid supplementation in liver disease.

Author

van Dijk, Anne M., Bruins Slot, Alexandra S., Portincasa, Piero, Siegerink, Sebastiaan N., Chargi, Najiba, Verstraete, Carina J. R., de Bruijne, Joep, Vleggaar, Frank P., and van Erpecum, Karel J.

Subjects
BRANCHED chain amino acids, LIVER diseases, PARACENTESIS, AMINO acids, DIETARY supplements, ESOPHAGEAL varices, NUTRITIONAL status
Abstract

Background: Dietary supplementation with branched‐chain amino acids (BCAA) is often used in cirrhotic patients to improve nutritional status. We wanted to explore the evidence for BCAA supplementation in chronic liver disease. Methods: We searched MEDLINE and EMBASE for studies with BCAA supplementation with the presence of a disease‐control group (placebo or no intervention) using search terms 'liver cirrhosis', 'hepatocellular carcinoma', 'branched chain amino acids' and relevant synonyms. Risk of bias was assessed using ROBINS‐I and RoB 2.0 tools. Meta‐analyses were performed with a random‐effects model. Results were reported following EQUATOR guidelines. Results: Of 3378 studies screened by title and abstract, 54 were included (34 randomized controlled trials, 5 prospective case–control studies, 13 retrospective case–control studies: in total 2308 patients BCAA supplementation, 2876 disease‐controls). Risk of bias was high/serious for almost all studies. According to meta‐analyses, long‐term (at least 6 months) BCAA supplementation in cirrhotic patients significantly improved event‐free survival (p =.008; RR.61 95% CI.42–.88) and tended to improve overall survival (p =.05; RR.58 95% CI.34–1.00). Two retrospective studies suggested the beneficial effects during sorafenib for hepatocellular carcinoma. Available studies reported no beneficial effects or contradictory results of BCAA after other specific therapeutic interventions (resection or radiological interventions for hepatocellular carcinoma, liver transplantation, paracentesis or variceal ligation). No convincing beneficial effects of BCAA supplementation on liver function, nutritional status or quality of life were found. No study reported serious side effects of BCAA. Conclusions: Prophylactic BCAA supplementation appears safe and might improve survival in cirrhotic patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

40. Risk factors for primary sclerosing cholangitis

Author

Boonstra, Kirsten, de Vries, Elisabeth M. G., van Geloven, Nan, van Erpecum, Karel J., Spanier, Marcel, Poen, Alexander C., van Nieuwkerk, Carin M., Witteman, Ben J., Tuynman, Hans A., Naber, Anton H., Kingma, Paul J., Beuers, Ulrich, and Ponsioen, Cyriel Y.

Published
2016
Full Text
View/download PDF

41. Liver‐related complications before and after successful treatment of chronic hepatitis C virus infection in people with inherited bleeding disorders.

Author

Isfordink, Cas J., van Erpecum, Karel J., Fischer, Kathelijn, van der Valk, Paul R., van Vulpen, Lize F. D., Schutgens, Roger E. G., Arends, Joop E., and Mauser‐Bunschoten, Evelien P.

Subjects
*HEPATITIS C, *CHRONIC hepatitis C, *TREATMENT effectiveness, *HEPATITIS C virus
Abstract

Introduction: With availability of direct‐acting antivirals (DAA), most persons with inherited bleeding disorders are currently cured of hepatitis C virus (HCV) infection. The risk of liver‐related complications following HCV cure has not been reported for this population. Aim: Reporting liver‐related complications during long‐term chronic HCV infection and following sustained virological response (SVR) in this population. Methods: Retrospective follow‐up of a prospective single‐centre cohort of HCV antibody‐positive persons with inherited bleeding disorders. Primary endpoint was liver‐related complications [hepatocellular carcinoma (HCC), decompensated cirrhosis, bleeding gastroesophageal varices]. Liver‐related complications were reported separately during chronic HCV and following SVR, stratified for interferon‐based and DAA‐based SVR. Results: In total 309/381 (81%) HCV antibody‐positive individuals developed chronic HCV infection. Median follow‐up was 44 years [interquartile range (IQR): 34–50]. Liver‐related complications occurred in 36/309 (12%) of individuals with chronic HCV infection after median 31 years of chronic infection. Of 199 individuals with SVR, 97 were cured with interferon‐based regimens and 102 with DAA after median infection durations of 29 and 45 years, respectively. At end of follow‐up, respectively, 21% and 42% had advanced fibrosis or cirrhosis. Post‐SVR, seven (4%) individuals had a liver‐related complication, mainly HCC (n = 4). Incidence of liver‐related complications per 100 patient‐years post‐SVR follow‐up was.2 for interferon‐cured and 1.0 for DAA‐cured individuals (p =.01). Conclusion: Successful HCV treatment does not eliminate the risk of liver‐related complications in persons with inherited bleeding disorders. Due to higher baseline risk, incidence was higher after DAA than interferon‐based SVR. We advise continuing HCC surveillance post‐SVR in all with advanced fibrosis or cirrhosis. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results